Neuberger Berman Group
FPRX

Neuberger Berman Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Neuberger Berman Group’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-13,276
Closed -$697K – 1669
2016
Q3 		$697K Buy
+13,276
New +$634K ﹤0.01% 1192

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Neuberger Berman Group's FPRX Position: Q4 2016 in Review

Neuberger Berman Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2016, closing a stake of 13,276 shares — an estimated $697K sold.

Neuberger Berman Group first reported a position in FPRX in Q3 2016 and held it in 1 quarter. The position peaked at $697K in Q3 2016. 172 funds tracked by Wall St. Rank hold FPRX as of Q4 2016.

  • Neuberger Berman Group reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Neuberger Berman Group sold 13,276 Five Prime Therapeutics, Inc. shares in Q4 2016, an estimated $697K.
  • Neuberger Berman Group first reported a position in Five Prime Therapeutics, Inc. in Q3 2016 and held it in 1 quarter.
  • Neuberger Berman Group's Five Prime Therapeutics, Inc. position peaked at $697K in Q3 2016.
  • 172 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2016.

Based on Neuberger Berman Group's 13F filing for Q4 2016, filed 6 Feb 2017.